Subjects -> MEDICAL SCIENCES (Total: 8529 journals)
    - ANAESTHESIOLOGY (120 journals)
    - CARDIOVASCULAR DISEASES (332 journals)
    - DENTISTRY (292 journals)
    - ENDOCRINOLOGY (150 journals)
    - FORENSIC SCIENCES (41 journals)
    - HEMATOLOGY (155 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (167 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2342 journals)
    - NURSES AND NURSING (362 journals)
    - OBSTETRICS AND GYNECOLOGY (207 journals)
    - ONCOLOGY (381 journals)
    - OTORHINOLARYNGOLOGY (82 journals)
    - PATHOLOGY (98 journals)
    - PEDIATRICS (273 journals)
    - PSYCHIATRY AND NEUROLOGY (822 journals)
    - RESPIRATORY DISEASES (103 journals)
    - RHEUMATOLOGY (78 journals)
    - SPORTS MEDICINE (81 journals)
    - SURGERY (401 journals)

RADIOLOGY AND NUCLEAR MEDICINE (192 journals)                     

Showing 1 - 192 of 192 Journals sorted alphabetically
Abdominal Radiology     Hybrid Journal   (Followers: 20)
Academic Radiology     Hybrid Journal   (Followers: 27)
Acta Cytologica     Hybrid Journal   (Followers: 3)
Acta Radiologica     Hybrid Journal   (Followers: 2)
Acta Radiologica Open     Open Access   (Followers: 3)
Acta Radiológica Portuguesa     Open Access  
Advanced Structural and Chemical Imaging     Open Access   (Followers: 2)
Advances in Computed Tomography     Open Access   (Followers: 3)
Advances in Radiation Oncology     Open Access   (Followers: 3)
AINS - Anasthesiologie - Intensivmedizin - Notfallmedizin - Schmerztherapie     Hybrid Journal   (Followers: 5)
Alasbimn Journal     Open Access   (Followers: 2)
American Journal of Neuroradiology     Full-text available via subscription   (Followers: 20)
American Journal of Roentgenology     Full-text available via subscription   (Followers: 34)
Annals of Nuclear Medicine     Hybrid Journal   (Followers: 4)
Annals of the ICRP     Hybrid Journal   (Followers: 4)
Applied In Vitro Toxicology     Hybrid Journal   (Followers: 2)
Applied Radiology     Full-text available via subscription   (Followers: 10)
Arab Journal of Interventional Radiology     Open Access   (Followers: 1)
Asia Oceania Journal of Nuclear Medicine & Biology     Open Access   (Followers: 3)
Bangladesh Journal of Nuclear Medicine     Open Access  
Belgian Journal of Radiology     Open Access   (Followers: 3)
Biomedical Imaging and Intervention Journal     Open Access   (Followers: 4)
BJR     Hybrid Journal   (Followers: 21)
BJR | case reports     Open Access   (Followers: 6)
BMC Medical Imaging     Open Access   (Followers: 10)
Canadian Association of Radiologists Journal     Full-text available via subscription   (Followers: 2)
Cancer Biotherapy & Radiopharmaceuticals     Hybrid Journal   (Followers: 1)
Cancer Radiothérapie     Full-text available via subscription   (Followers: 1)
Case Reports in Radiology     Open Access   (Followers: 12)
Chinese Journal of Academic Radiology     Hybrid Journal  
Clinical and Translational Imaging     Hybrid Journal   (Followers: 1)
Clinical and Translational Radiation Oncology     Open Access   (Followers: 1)
Clinical Imaging     Hybrid Journal   (Followers: 5)
Clinical Mass Spectrometry     Open Access  
Clinical Neuroradiology     Hybrid Journal   (Followers: 3)
Clinical Nuclear Medicine     Hybrid Journal   (Followers: 2)
Clinical Radiology     Hybrid Journal   (Followers: 18)
Computerized Medical Imaging and Graphics     Hybrid Journal   (Followers: 14)
Concepts in Magnetic Resonance Part A     Open Access   (Followers: 1)
Concepts in Magnetic Resonance Part B, Magnetic Resonance Engineering     Open Access   (Followers: 1)
Concussion     Open Access  
Contemporary Diagnostic Radiology     Full-text available via subscription   (Followers: 3)
Contrast Media & Molecular Imaging     Open Access   (Followers: 2)
Critical Ultrasound Journal     Open Access   (Followers: 3)
Current Medical Imaging Reviews     Hybrid Journal   (Followers: 3)
Current Problems in Diagnostic Radiology     Hybrid Journal   (Followers: 10)
Current Radiology Reports     Hybrid Journal   (Followers: 4)
Dentomaxillofacial Radiology     Hybrid Journal   (Followers: 4)
Der Nuklearmediziner     Hybrid Journal  
Der Radiologe     Hybrid Journal   (Followers: 1)
Diagnostic and Interventional Radiology     Open Access   (Followers: 6)
Digestive Disease Interventions     Hybrid Journal  
DNA and RNA Nanotechnology     Open Access   (Followers: 6)
Egyptian Journal of Radiology and Nuclear Medicine     Open Access   (Followers: 1)
EJNMMI Radiopharmacy and Chemistry     Open Access  
Emergency Radiology     Hybrid Journal   (Followers: 8)
Endoscopic Ultrasound     Open Access  
European Journal of Nanomedicine     Hybrid Journal   (Followers: 1)
European Journal of Nuclear Medicine and Molecular Imaging     Hybrid Journal   (Followers: 12)
European Journal of Radiology     Hybrid Journal   (Followers: 21)
European Journal of Radiology Open     Open Access   (Followers: 9)
European Radiology     Hybrid Journal   (Followers: 17)
European Radiology Experimental     Open Access  
European Radiology Supplements     Hybrid Journal   (Followers: 3)
Feuillets de Radiologie     Full-text available via subscription  
Frontiers in Neurogenesis     Open Access   (Followers: 2)
IEEE Transactions on Medical Imaging     Hybrid Journal   (Followers: 28)
IEEE Transactions on Radiation and Plasma Medical Sciences     Hybrid Journal   (Followers: 3)
Imagen Diagnóstica     Full-text available via subscription  
Imaging Decisions MRI     Hybrid Journal   (Followers: 2)
Indian Journal of Nuclear Medicine     Open Access   (Followers: 2)
Indian Journal of Radiology and Imaging     Open Access   (Followers: 4)
Insights into Imaging     Open Access   (Followers: 4)
International Journal of Biomedical Nanoscience and Nanotechnology     Hybrid Journal   (Followers: 8)
International Journal of Computer Assisted Radiology and Surgery     Hybrid Journal   (Followers: 6)
International Journal of Medical Physics, Clinical Engineering and Radiation Oncology     Open Access   (Followers: 10)
International Journal of Nanomedicine     Open Access   (Followers: 2)
International Journal of Radiation Biology     Hybrid Journal   (Followers: 6)
International Journal of Radiology and Radiation Oncology     Open Access   (Followers: 1)
International Journal of Tomography & Simulation     Full-text available via subscription   (Followers: 1)
Interventional Neuroradiology     Hybrid Journal   (Followers: 1)
Interventionelle Radiologie Scan     Hybrid Journal   (Followers: 1)
Investigative Radiology     Hybrid Journal   (Followers: 10)
Iranian Journal of Medical Physics     Open Access  
Iranian Journal of Nuclear Medicine     Open Access   (Followers: 1)
Iranian Journal of Radiology     Open Access   (Followers: 5)
Japanese Journal of Radiology     Hybrid Journal   (Followers: 4)
Journal de Radiologie     Full-text available via subscription  
Journal de Radiologie Diagnostique et Interventionnelle     Full-text available via subscription   (Followers: 2)
Journal of Nanomedicine & Nanotechnology     Open Access   (Followers: 1)
Journal of Clinical Imaging Science     Open Access   (Followers: 3)
Journal of Clinical Interventional Radiology ISVIR     Open Access   (Followers: 2)
Journal of Clinical Ultrasound     Hybrid Journal   (Followers: 6)
Journal of Computer Assisted Tomography     Hybrid Journal   (Followers: 1)
Journal of Diagnostic Medical Sonography     Hybrid Journal  
Journal of Diagnostic Radiography and Imaging     Hybrid Journal   (Followers: 4)
Journal of Fetal Medicine     Hybrid Journal  
Journal of Global Radiology     Open Access   (Followers: 2)
Journal of Indian Academy of Oral Medicine and Radiology     Open Access   (Followers: 3)
Journal of Innovative Optical Health Sciences     Open Access  
Journal of Liver : Disease & Transplantation     Hybrid Journal   (Followers: 7)
Journal of Magnetic Resonance     Hybrid Journal   (Followers: 14)
Journal of Magnetic Resonance Imaging     Hybrid Journal   (Followers: 17)
Journal of Medical Imaging     Free   (Followers: 5)
Journal of Medical Imaging and Radiation Oncology     Hybrid Journal   (Followers: 3)
Journal of Medical Imaging and Radiation Sciences     Hybrid Journal   (Followers: 5)
Journal of Medical Radiation Sciences     Open Access   (Followers: 3)
Journal of Neuroradiology     Full-text available via subscription   (Followers: 4)
Journal of Nuclear Medicine     Full-text available via subscription   (Followers: 20)
Journal of Nuclear Medicine & Radiation Therapy     Open Access   (Followers: 3)
Journal of Nucleic Acids Investigation     Open Access   (Followers: 2)
Journal of Oral and Maxillofacial Radiology     Open Access   (Followers: 1)
Journal of Pediatric Neuroradiology     Hybrid Journal   (Followers: 3)
Journal of Radiation and Cancer Research     Open Access  
Journal of Radiation Research     Open Access   (Followers: 3)
Journal of Radiation Research and Applied Sciences     Open Access   (Followers: 2)
Journal of Radiobiology     Open Access   (Followers: 1)
Journal of Radiological Protection     Full-text available via subscription   (Followers: 4)
Journal of Radiology and Oncology     Open Access  
Journal of Radiology Nursing     Hybrid Journal   (Followers: 2)
Journal of Radiosurgery     Hybrid Journal   (Followers: 2)
Journal of Radiotherapy in Practice     Hybrid Journal   (Followers: 7)
Journal of the American College of Radiology     Hybrid Journal   (Followers: 10)
Journal of Thoracic Imaging     Hybrid Journal   (Followers: 3)
Journal of Vascular and Interventional Radiology     Hybrid Journal   (Followers: 13)
La radiologia medica     Hybrid Journal  
Magnetic Resonance Imaging     Hybrid Journal   (Followers: 7)
Magnetic Resonance Imaging Clinics of North America     Full-text available via subscription   (Followers: 7)
Magnetic Resonance in Medicine     Hybrid Journal   (Followers: 16)
Medical Image Analysis     Hybrid Journal   (Followers: 15)
Medical Imaging and Radiology     Open Access   (Followers: 7)
Nepalese Journal of Radiology     Open Access   (Followers: 1)
Neurographics     Free   (Followers: 3)
NeuroImage : Clinical     Open Access   (Followers: 15)
Neuroradiology     Hybrid Journal   (Followers: 9)
Neuroradiology Journal The     Hybrid Journal   (Followers: 1)
Nuclear Medicine and Biology     Hybrid Journal   (Followers: 4)
Nuclear Medicine and Molecular Imaging     Hybrid Journal   (Followers: 4)
Nuclear Medicine Communications     Hybrid Journal   (Followers: 2)
Nuclear Medicine Review     Open Access   (Followers: 2)
Nuklearmedizin / NuclearMedicine     Hybrid Journal  
Open Journal of Clinical Diagnostics     Open Access   (Followers: 1)
Open Journal of Medical Imaging     Open Access   (Followers: 1)
Open Journal of Radiology     Open Access   (Followers: 4)
Open Medical Imaging Journal     Open Access  
Oral Radiology     Hybrid Journal   (Followers: 1)
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology     Full-text available via subscription   (Followers: 9)
Pediatric Radiology     Hybrid Journal   (Followers: 6)
Physica Medica     Full-text available via subscription   (Followers: 3)
Progress in Nuclear Magnetic Resonance Spectroscopy     Full-text available via subscription   (Followers: 8)
Radiation Protection and Environment     Open Access   (Followers: 1)
Radiatsionnaya Gygiena = Radiation Hygiene     Open Access  
Radiographics     Full-text available via subscription   (Followers: 27)
Radiography     Full-text available via subscription   (Followers: 7)
Radiography Open     Open Access   (Followers: 1)
Radiología     Full-text available via subscription   (Followers: 1)
Radiología (English Edition)     Full-text available via subscription  
Radiologia Brasileira     Open Access  
Radiologic Clinics of North America     Full-text available via subscription   (Followers: 19)
Radiologie up2date     Hybrid Journal   (Followers: 1)
Radiology     Full-text available via subscription   (Followers: 42)
Radiology Case Reports     Open Access   (Followers: 2)
Radiology of Infectious Diseases     Open Access   (Followers: 3)
Radiology Research and Practice     Open Access   (Followers: 3)
Radiopraxis     Hybrid Journal  
Reports in Medical Imaging     Open Access  
Research and Reports in Nuclear Medicine     Open Access   (Followers: 1)
Research Journal of Radiology     Open Access   (Followers: 5)
Revista Argentina de Radiología / Argentinian Journal of Radiology     Open Access  
Revista Chilena de Radiologia     Open Access  
Revista Española de Medicina Nuclear e Imagen Molecular     Full-text available via subscription   (Followers: 2)
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)     Full-text available via subscription  
Revista Internacional de Ciencias Podológicas     Open Access  
Seminars in Interventional Radiology     Hybrid Journal   (Followers: 6)
Seminars in Musculoskeletal Radiology     Hybrid Journal   (Followers: 6)
Seminars in Nuclear Medicine     Hybrid Journal   (Followers: 5)
Seminars in Roentgenology     Hybrid Journal   (Followers: 3)
Seminars in Ultrasound, CT and MRI     Hybrid Journal   (Followers: 9)
Shadows : The New Zealand Journal of Medical Radiation Technology     Full-text available via subscription   (Followers: 2)
Skeletal Radiology     Hybrid Journal   (Followers: 10)
Solid State Nuclear Magnetic Resonance     Hybrid Journal   (Followers: 3)
South African Journal of Radiology     Open Access   (Followers: 1)
South African Radiographer     Full-text available via subscription  
Sri Lanka Journal of Radiology     Open Access  
Surgical and Radiologic Anatomy     Hybrid Journal   (Followers: 6)
Techniques in Vascular and Interventional Radiology     Full-text available via subscription   (Followers: 8)
Topics in Magnetic Resonance Imaging     Hybrid Journal   (Followers: 3)
Ultraschall in der Medizin - European Journal of Ultrasound     Hybrid Journal   (Followers: 2)
Ultrasonic Imaging     Hybrid Journal   (Followers: 2)
Ultrasound Quarterly     Hybrid Journal   (Followers: 2)
West African Journal of Radiology     Open Access   (Followers: 1)
World Journal of Nuclear Medicine     Open Access   (Followers: 2)


Similar Journals
Journal Cover
Annals of Nuclear Medicine
Journal Prestige (SJR): 0.687
Citation Impact (citeScore): 2
Number of Followers: 4  
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 1864-6433 - ISSN (Online) 0914-7187
Published by Springer-Verlag Homepage  [2625 journals]
  • Quantitative evaluation of salivary gland scintigraphy in Sjögren’s
           syndrome: comparison of diagnostic efficacy and relationship with
           pathological features of the salivary glands
    • Abstract: Objective The value of salivary gland scintigraphy (SGS) in the evaluation of Sjögren’s syndrome (SS) remains controversial. The aim of this study was to evaluate the diagnostic efficacy of quantitative SGS in patients with xerostomia and to assess the correlation between scintigraphic parameters and pathological features of salivary glands. Methods Medical records of 165 patients with xerostomia who underwent [99mTc] pertechnetate SGS and labial biopsy were retrospectively reviewed. The maximum accumulation ratio (MAR), maximum secretion ratio (MSR), and time interval from stimulation to minimum count (Tmin) of the parotid glands were calculated to quantify the glandular activity. Furthermore, pre-stimulatory oral activity index (PRI) and post-stimulatory oral activity index (POI) were calculated to quantify the oral activity. Results All parameters except for Tmin were significantly lower in patients with SS than in those without SS. Among the five SGS parameters, PRI showed the highest areas under the curve value (0.9005; p < 0.001), and PRI > 32.75 was associated with a sensitivity of 78.5% and specificity of 86.4% for the diagnosis of SS. A decrease in MAR, MSR, PRI, and POI and an increase in Tmin correlate significantly with the histopathologic grade of labial gland biopsy and disease severity of SS. No significant differences in glandular parameters (MAR, MSR, and Tmin) were found between the non-SS and early-stage SS groups. Conclusion Conventional scintigraphic parameters could be used as simple, reliable, and sensitive indicators for the early diagnosis of SS and determination of disease severity.
      PubDate: 2020-04-01
  • Full report on a survey of adverse reactions to radiopharmaceuticals from
           1975 to 2017 in Japan
    • Abstract: Objective This pharmacovigilance-based survey was aimed at determining the prevalence of, and association between, radiopharmaceuticals and adverse reactions to radiopharmaceuticals from 1975 to 2017 in Japan. Methods The Subcommittee for Safety Issues of Radiopharmaceuticals of the Japan Radioisotope Association’s Medical Science and Pharmaceutical Committee mailed a form for reporting adverse reactions to radiopharmaceuticals to all institutes performing nuclear medicine examinations in Japan. This investigation included adverse reactions to diagnostic radiopharmaceuticals labeled with both single-photon- and positron-emitting radionuclides and therapeutic sodium iodide labeled with 131I. Each institute returned the reporting form to the subcommittee each time an adverse reaction occurred. Results Replies were obtained from 75% of the institutions. In total, 1099 adverse reactions were reported from 46,645,580 radiopharmaceutical administrations, giving a prevalence of 2.4 adverse reactions per 100,000 administrations (95% confidence interval 2.2–2.5). Adverse reactions were most frequently observed for 131I-iodomethylnorcholesterol (230.1/105 administrations), followed by 131I-HSA (76.3/105 administrations), 131I-sodium iodohippurate (31.2/105 administrations), and 99mTc-DTPA (12.0/105 administrations). Comparison of adverse reactions between before and after 1997 revealed that prevalence dropped from 3.7/105 administrations (95% confidence interval 3.5–4.1) to 1.5/105 administrations (95% confidence interval 1.4–1.6). During the study period, vasovagal reactions accounted for 50.3% of adverse reactions, fever for 7.5%, allergic reactions for 25.7%, and other for 16.5%; 3.7% of all adverse reactions were considered severe but none were lethal. A definite, probable, possible, less likely, and uncertain causal relationship with radiopharmaceuticals was observed in 13.1%, 33.7%, 39.9%, 6.2%, and 7.1% of adverse reactions, respectively. Conclusions These results suggest that nuclear medicine staff must be aware of the possibility of adverse reactions from radiopharmaceuticals, despite their rarity.
      PubDate: 2020-04-01
  • The role of epsilon phenotype in brain glucose consumption in
           Alzheimer’s disease
    • Abstract: Objective The aim of our study was to investigate the impact of the epsilon phenotype in brain glucose consumption in a population with Alzheimer’s disease. Methods Statistical Parametric Mapping (SPM8) was used to investigate differences in brain glucose consumption (as detectable by means of 18F FDG-PET/CT) in the population examined. A total of 129 patients (72 females and 57 males) with a diagnosis of probable AD according to the NINCDS-ADRDA criteria underwent the PET/CT examination. The mean (SD) age of the patients was 70 (± 7) years; the mean Mini-Mental State Examination was 19(± 5.6). 59 expressed epsilon 4 phenotype (E4) and 70 expressed the epsilon 3 phenotype (E3). Cerebral spinal fluid amyloid, tau, and t-tau have been measured resulting equal to 367.4 (± 149.1), 584.7 (± 312.1), and 79.2(± 45.9) pg/ml, respectively. Patients with confirmed amyloid and Tau changes were classified as AD. Patients with amyloid changes but negative Tau, considered as high risk of AD, were classified as IAD. Age, sex, MMSE, scholarship, and CSF parameters were used as a covariate in the SPM analyses. Results We did not find significant differences in age, gender, and MMSE and CSF parameters among groups. In the analysis of the AD group as compared to AD-E3, AD-E4 subjects show a significant reduction of brain glucose consumption in inferior frontal gyrus bilaterally (BA 45, BA 47). In the analysis of the IAD group as compared to IAD-E3, IAD-E4 subjects show a significant reduction of brain glucose consumption in right in medial, middle, and superior frontal gyrus (BA10, BA11), and in left medial and middle frontal gyrus (BA10, BA11). The differences between IAD-E3 and AD-E3 and between IAD-E4 and AD-E4 (and vice versa analysis) resulted not significant. Conclusions APO-e4 is related to a major involvement of the frontal cortex confirming its role of risk factor in AD, while APO-3 seems not related to a specific pattern, supporting the hypothesis of neutral/protective role in AD.
      PubDate: 2020-04-01
  • The value of Bayesian penalized likelihood reconstruction for improving
           lesion conspicuity of malignant lung tumors on 18 F-FDG PET/CT: comparison
           with ordered subset expectation maximization reconstruction incorporating
           time-of-flight model and point spread function correction
    • Abstract: Objective To evaluate the value of Bayesian penalized likelihood (BPL) reconstruction for improving lesion conspicuity of malignant lung tumors on 18F-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography computed tomography (PET/CT) as compared with the ordered subset expectation maximization (OSEM) reconstruction incorporating time-of-flight (TOF) model and point-spread-function (PSF) correction. Methods Twenty-nine patients with primary or metastatic lung cancers who underwent 18F-FDG PET/CT were retrospectively studied. PET images were reconstructed with OSEM + TOF, OSEM + TOF + PSF, and BPL with noise penalty strength β-value of 200, 400, 600, and 800. The signal-to-noise ratio (SNR) was determined in normal liver parenchyma. Lung lesion conspicuity was evaluated in 50 lung lesions by using a 4-point scale (0, no visible; 1, poor; 2, good; 3, excellent conspicuity). Two observers were independently asked to choose the most preferred reconstruction for detecting the lung lesions on a per-patient level. The maximum standardized uptake value (SUVmax) was measured in each of the 50 lung lesions. Results Liver SNR on the images reconstructed by BPL with β-value of 600 and 800 (17.8 ± 3.7 and 22.5 ± 4.6, respectively) was significantly higher than that by OSEM + TOF + PSF (15.0 ± 3.4, p < 0.0001). BPL with β-value of 600 was chosen most frequently as the preferred reconstruction algorithm for lung lesion assessment by both observers. The conspicuity score of the lung lesions < 10 mm in diameter on images reconstructed by BPL with β-value of 600 was significantly greater than that with OSEM + TOF + PSF (2.2 ± 0.8 vs 1.6 ± 0.9, p < 0.0001), while the conspicuity score of the lesions ≥ 10 mm in diameter was not significantly different between BPL with β-value of 600 and OSEM + TOF + PSF. The mean SUVmax was increased by BPL with β-value of 600 for the lung lesions with < 10 mm in diameter, compared to OSEM + TOF + PSF (3.4 ± 3.1 to 4.2 ± 3.5, p = 0.001). In contrast, BPL with β-value of 600 did not provide increased SUVmax for the lesions  ≥ 10 mm in diameter. Conclusion BPL reconstruction significantly improves the detection of small inconspicuous malignant tumors in the lung, improving the diagnostic performance of PET/CT.
      PubDate: 2020-04-01
  • Clinical implication of myocardial FDG uptake pattern in oncologic PET:
           retrospective comparison study with stress myocardial perfusion imaging as
           the reference standard
    • Abstract: Objective The purpose of this study was to determine the clinical implication of the myocardial FDG uptake patterns by comparing with the results of stress myocardial perfusion imaging (MPI) as the reference standard. Methods By reviewing the medical records, 86 pairs of stress MPI and FDG PET/CT of 84 patients who underwent stress MPI and oncologic FDG PET/CT in 1 month were included in this study. The patterns of the myocardial FDG uptake were classified into five patterns such as ‘low’, ‘diffuse’, ‘basal ring’, ‘focal high’, and ‘focal defect on diffuse high’. MPI was evaluated using a 5-point scoring model ranging from 0 (normal uptake) to 4 (uptake absent) based on the 17-segment model. The summed stress score of 4 or higher was defined as ‘abnormal MPI’. Factors predictive of abnormal MPI were analyzed using a log-rank multivariate test and p < 0.05 was set as significant. Results Abnormal MPI was observed in only 16 of 36 (44%) patients with ‘low’ pattern, 10 of 23 (43%) patients with ‘diffuse high’ pattern, and 1 of 9 (11%) patients with ‘basal ring’ pattern, but in 8 of 9 (89%) patients with ‘focal high’ pattern, and 8 of 9 (89%) patients with ‘focal defect on diffuse high’ pattern. The log-rank multivariate test revealed that ‘focal high’ and ‘focal defect on diffuse high’ pattern were correlated with an abnormal MPI. Conclusions These results indicate that further cardiac work-up might be helpful in the patients with ‘focal high’ pattern or ‘focal defect on diffuse high’ pattern of myocardial FDG at oncologic PET. A prospective study should be needed to further support this conclusion.
      PubDate: 2020-04-01
  • Accuracy of Oral 67 Gallium Citrate Scintigraphy in assessment of
           inflammatory activity of Crohn’s disease
    • Abstract: Aim The main goal in Crohn´s disease (CD) is a sustained suppression of inflammatory activity associated with mucosa healing in endoscopic evaluation. During clinical routine, there are small numbers of good markers to monitor inflammatory activity under treatment. We postulated that Oral 67Gallium Citrate Scintigraphy is able to mark inflammatory disease in mucosa and deep inflammation in CD, when used in oral form. Objective Measure the accuracy of Oral 67Gallium Citrate Scintigraphy in intestinal inflammatory activity of Crohn´s disease. Patients and methods In a prospective consecutive cross-sectional study from January 2018 to June 2019, the ileocolonic region of 32 patients with CD were studied by dividing into four regions of interest (ROI) from the ileum to the rectum. A total of 128 intestinal segments were analyzed in cluster data. Accuracy values of Oral 67Gallium Scintigraphy and colonoscopy tests were evaluated with the histological reference test. Values of the respective receiver operating characteristic (ROC) curves were obtained  and compared. The reliability between the tests was evaluated by Kappa statistical with the segment-level analyses using variance adjustments. All statistical analyses were performed with a test significance level of 0.05. Results The study population included 32 patients with CD (10 men, 22 women; average age 39 years). Disease time was five years on average. Anti-TNFs treatment was found in 71%. The most found phenotype of the Montreal classification was L3. Differences in ROC curves for colonoscopy (0.94) and Oral 67Ga Scintigraphy (0.96) did not show significant value (p = 0.32). The sensitivity of scintigraphy to detect intestinal inflammatory activity in CD was 64%, specificity of 96% and accuracy of 84%. A high agreement was found between oral scintigraphy and histological measurements with kappa = 0.64. Conclusions Oral 67Ga Scintigraphy had similar accuracy and agreement compared to colonoscopy in the identification of inflammatory activity in Crohn´s Disease. This new approach may be useful and less invasive for long term follow-ups.
      PubDate: 2020-04-01
  • Toyama H, Li Y, Hatazawa J, Huang G, Kubota K (eds): PET/CT for
           inflammatory diseases: basic sciences, typical cases, and review
    • PubDate: 2020-03-28
  • Retrospective correlation of 68 ga-psma uptake with clinical parameters in
           prostate cancer patients undergoing definitive radiotherapy
    • Abstract: Objective The aim of the study is to investigate the correlation between the intensity of prostate-specific membrane antigen (PSMA) uptake in primary tumor and clinico-pathological characteristics of non-metastatic prostate cancer patients treated with definitive radiotherapy (RT). Methods Using the clinical data of 201 prostate cancer patients who were referred for 68 Ga-PSMA-positron emission tomography (PET/CT) for staging and RT planning, we analyzed the correlations among intermediate- or high-risk disease based on Gleason score (GS), prostate-specific antigen (PSA) level, D’Amico risk group classification, and maximum standardized uptake (SUVmax) of primary tumor. Results Primary tumor was visualized via 68 Ga-PSMA-PET/CT scan in 192 patients (95.5%). The median SUVmax of primary tumor and metastatic lymph node were 13.2 (range 3.3–83.7) and 11.4 (range 3.6–64.5), respectively. A significant moderate correlation was observed between PSA level and median tumor SUVmax as measured by 68 Ga-PSMA-PET/CT (Spearman = 0.425; p < 0.001). Patients with serum PSA > 10 ng/mL, GS > 7, D’Amico high-risk group classification, and pelvic lymph node metastasis had significantly higher tracer uptake in primary tumor than their counterparts. The median SUVmax of primary tumor was highest in patients with GS 9. The primary tumor detection rates of 68 Ga-PSMA-PET/CT were 83%, 92%, and 99% for patients with serum PSA ≤ 5.0 ng/mL (14 patients, 7%), PSA 5.1–10.0 ng/mL (45 patients, 22%), and PSA > 10 ng/mL (142 patients, 71%), respectively. Conclusions We demonstrated a correlation between prostate tumor characteristics and PSMA tracer uptake. Patients with serum PSA > 10 ng/mL, GS > 7, D’Amico high-risk group classification, and pelvic lymph node metastasis had significantly higher SUV than their counterparts. In addition, the primary tumor detection rate was higher in patients with serum PSA > 10 ng/mL and GS > 7.
      PubDate: 2020-03-27
  • High-dose 131 I-metaiodobenzylguanidine therapy in patients with high-risk
           neuroblastoma in Japan
    • Abstract: Objective The aim of the study was to investigate the outcomes and prognostic factors of high-dose 131I-metaiodobenzylguanidine (131I-MIBG) therapy in patients with refractory or relapsed neuroblastoma (NBL) in Japan. Methods We retrospectively analyzed 20 patients with refractory or relapsed high-risk NBL who underwent 131I-MIBG therapy with an administration dose ranging from 444 to 666 MBq/kg at Kanazawa University Hospital, Japan, between September 2008 and September 2013. We focused on measurements regarding their initial responses, prognostic factors, survivals, and toxicities following 131I-MIBG therapy using our hospital data and questionnaires from the hospitals that these patients were initially referred from. Furthermore, we performed Kaplan–Meier survival analysis to evaluate event-free survival (EFS) and overall survival (OS). Results In 19 patients with complete follow-up data, the median age at first 131I-MIBG treatment was 7.9 years (range 2.5–17.7 years). Following 131I-MIBG therapy, 17 of the 19 patients underwent stem-cell transplantations, and their treatment response was either complete (CR) or partial (PR) in three and two cases, respectively. The EFS and OS rates at 1 year following 131I-MIBG therapy were 42% and 58%, respectively, and those at 5 years following 131I-MIBG therapy were 16% and 42%, respectively. Using the two-sample log-rank test, the OS time following 131I-MIBG therapy was significantly longer for < 3-year time interval between the initial diagnosis and 131I-MIBG therapy (p = 0.017), Curie score < 16 just before 131I-MIBG therapy (p = 0.002), without pain (p = 0.002), without both vanillylmandelic acid (VMA) and homovanillic acid (HVA) elevation (p = 0.037) at 131I-MIBG therapy, and with CR or PR following 131I-MIBG therapy (p = 0.015). Although severe hematological toxicities were identified in all 19 patients, severe nonhematological toxicity was not recorded in any patient, except for one patient with grade 3 anorexia and nausea. Conclusions High-dose 131I-MIBG therapy in patients with refractory or relapsed high-risk NBL can provide a favorable prognosis without severe nonhematological toxicities. Better prognosis may be anticipated in patients with the initial good response, no pain at 131I-MIBG therapy, no VMA and HVA elevation at 131I-MIBG therapy, low Curie score (< 16) just before 131I-MIBG therapy, and short time interval (< 3 years) between the initial diagnosis and 131I-MIBG therapy.
      PubDate: 2020-03-26
  • Ten-year prospective evaluation of whole-body cancer screening with
           multiple modalities including [ 18 F]fluorodeoxyglucose positron emission
           tomography in a healthy population
    • Abstract: Purpose To prospectively evaluate the value of whole-body cancer screening with multiple modalities including FDG-PET in a healthy population. Methods The study was conducted in 1197 healthy individuals aged ≥ 35 years at enrollment between August 2003 and July 2004. All participants were scheduled to receive annual whole-body cancer screening five times (screening period) with subsequent long-term follow-up (follow-up period). The endpoints of the study were definitive cancer diagnosis, cancer-related death, and all-cause death. Results The follow-up rate was 99.8% for the screening period and 96.2% for the follow-up period. Forty-five cancers were confirmed during the screening period (August 2003 to July 2009), and 37 of the 45 were detected by the screening. Fourteen of the 45 were PET positive. Sixteen, 5, 4, 9 and 11 cancers were confirmed after the first, the second, the third, the fourth, and the fifth (took 2 years) screening, respectively. Eight participants died, of whom five died of cancer. The rate of cancer incidence (per 100,000) of 628.7 (95% confidence interval [CI] 445.0–812.4) was significantly high, and the rates of cancer mortality and all-cause mortality of 69.9 (95% CI 8.6–131.1) and 111.8 (95% CI 34.3–189.2), respectively, were significantly low, compared with the corresponding rates of 379.3, 138.2 and 354.2, respectively, in the age-rank- and sex-matched general population. During the follow-up period (August 2009 to July 2013), 37 cancers were confirmed and 30 of the 37 were detected. Seven participants died, of whom three died of cancer. The rate of cancer incidence was 809.6 (95% CI 548.7–1070.5). The rates of cancer mortality and all-cause mortality of 65.6 (95% CI 0–139.9) and 153.2 (95% CI 39.7–266.6), respectively, were significantly low compared with 190.1 and 462.3, respectively, in the general population. Conclusion Cancer detection by PET alone was limited. While the high cancer incidence was attributed to the extensive screening, the low cancer and all-cause mortality may indicate the potential value of this type of cancer screening. Cancer incidence increases with aging and it has been shown that continuous screening may reduce the risk caused by the cancer progression.
      PubDate: 2020-03-21
  • Pet tracers for vulnerable plaque imaging
    • Abstract: Abstract Most of the acute ischemic events, such as acute coronary syndromes and stroke, are attributed to vulnerable plaques. These lesions have common histological and pathophysiological features, including inflammatory cell infiltration, neo-angiogenesis, remodelling, haemorrhage predisposition, thin fibrous cap, large lipid core, and micro-calcifications. Early detection of the presence of a plaque prone to rupture could be life-saving for the patient; however, vulnerable plaques usually cause non-haemodynamically significant stenosis, and anatomical imaging techniques often underestimate, or may not even detect, these lesions. Although ultrasound techniques are currently considered as the “first-line” examinations for the diagnostic investigation and treatment monitoring in patients with atherosclerotic plaques, positron emission tomography (PET) imaging could open new horizons in the assessment of atherosclerosis, given its ability to visualize metabolic processes and provide molecular-functional evidence regarding vulnerable plaques. Moreover, modern hybrid imaging techniques, combining PET with computed tomography or magnetic resonance imaging, can evaluate simultaneously both functional and morphological parameters of the atherosclerotic plaques, and are expected to significantly expand their clinical role in the future. This review summarizes current research on the PET imaging of the vulnerable atherosclerotic plaques, outlining current and potential applications in the clinical setting.
      PubDate: 2020-03-20
  • Ciliated muconodular papillary tumor of the lung: 18F-FDG PET/CT findings
           of 15 cases
    • Abstract: Objective Ciliated muconodular papillary tumor (CMPT) is a rare lung tumor that was first reported in 2002. This study assessed 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) findings of CMPT of the lung. Methods FDG PET/CT findings of 15 patients (eight men and seven women; median age, 67 years) with surgically resected CMPTs were retrospectively analyzed. Size, location, and maximum standardized uptake values (SUVmax) of CMPTs were measured. Histopathological features of the resected tumors were assessed and compared with the FDG PET/CT findings. Results CMPTs were detected as a small pulmonary nodule in all 15 patients. Twelve of 15 tumors were found in the lower lobe of the lung. Mean maximal diameter of the tumors was 9 mm (range 6–14 mm). All but one tumor showed low FDG uptake, with a SUVmax ranging from 0.57 to 1.35. The remaining tumor showed moderate FDG uptake, with a SUVmax of 3.67. Pathologically, tumors with low FDG uptake contained various amounts of mucin and no or only a small amount of lymphocyte infiltration. In contrast, the tumor with moderate FDG uptake had a large cellular component and prominent lymphocyte infiltration. Conclusion CMPT typically shows low FDG uptake.
      PubDate: 2020-03-14
  • Feasibility of gamma camera-based GFR measurement using renal depth
           evaluated by lateral scan of 99m Tc-DTPA renography
    • Abstract: Objective Gamma camera-based measurement of glomerular filtration rate (GFR) with 99mTc-diethylenetriaminepentaacetic acid (DTPA) is an established non-invasive measurement of split renal function; however, it is not as accurate as the plasma sample method. Therefore, study into improving the accuracy of such method is clinically relevant. The aim of this study was to elucidate the feasibility of gamma camera-based GFR measurement using renal depth evaluated by lateral scan of 99mTc-DTPA renography and comparing the results with those of GFR using renal depth measured by CT, and three representative formulas. Methods The study population comprised 38 patients (median, 69 years; male 28, female 10; median estimated GFR, 67.4 ml/min) with renourinary disorders. Scintigraphy was performed after intravenous injection of 370 MBq 99mTc-DTPA by dynamic data acquisition for 20 min, followed by a bilateral static scan of the abdomen for 3 min. All patients underwent computed tomography (CT) within 2 months from renography. GFR was calculated by renography using renal depth determined in five ways; lateral scan of 99mTc-DTPA, CT, and three formulas previously created with using weight, height and age. GFRs were compared with estimated GFR (eGFR). The depth of both kidneys measured as described above was compared and evaluated the laterality of the renal depth. Results The median values of GFR calculated with renal depth determined by 99mTc-DTPA renography, CT, and the three formulas were 87.3, 83.9, 67.8, 68.3, and 71.5 ml/min, respectively. All of them correlated significantly with eGFR (r = 0.734, r = 0.687, r = 0.728, r = 0.726, and r = 0.686, respectively), however, no significant difference was observed among five correlation coefficients. Bland–Altman plot revealed that eGFR had error and fixed bias when compared with GFRs calculated using renal depth determined by renography, CT, and Taylor’s formula. The depth of both kidneys measured by 99mTc-DTPA renography was equivalent to that measured by CT, however, those measured by the three formulas were significantly smaller than that measured by 99mTc-DTPA renography. The depth of the right kidney was larger than that of the left kidney using all three formulas in all patients. However, CT detected only 66% of patients to have a deeper right kidney than left kidney. Conclusion Lateral scanning is a feasible procedure to measure renal depth for accurate and reasonable split GFR measurements using 99mTc-DTPA renography.
      PubDate: 2020-03-13
  • Relationships between amyloid levels, glucose metabolism, morphologic
           changes in the brain and clinical status of patients with Alzheimer’s
    • Abstract: Objective The current study was conducted to improve the understanding of relationships between regional cortical amyloid load, glucose metabolism, cortical morphology (volume), and severity of clinical symptoms in patients with AD, MCI, and age-matched controls. Methods To objectivize the radiological evaluation of patients with suspected AD, head-to-head multi-modality imaging studies were conducted using MRI and PET/CT with [18F]FDG and [18F]AV45 for visualization and quantitation of brain morphology, glucose metabolism, and amyloid levels, respectively. A total of 84 subjects was studied, including 33 patients with AD, 31 patients with MCI, and 20 age-matched healthy controls (HC). A new quantitative index was calculated as a ratio of regional SUV of [18F]AV45 (normalized to cerebellar cortex) over the corresponding regional SUV of [18F]FDG, divided by the corresponding regional volume, measured from the co-registered MRI and normalized to the normal age-matched control group (AV45/FDG/NVol index). Relationships between clinical scores (TMSE, ADAS) and AV45/FDG/NVol indices for different structures of the brain in study groups were determined using linear regression analyses. Results A significant direct linear correlation was observed between the AV45/FDG/NVol index and ADAS-Cog test score and an inverse correlation with TMSE score at baseline and with the degree of changes in ADAS and TMSE scores assessed one year later (disease progression). The observed correlations between AV45/FDG/NVol index and clinical scores were higher than those with MRI-based cortical volumes, FDG SUV, or cerebellum-normalized AV45 SUV alone. Conclusions Current study demonstrated that AV45/FDG/NVol index mapping of the brain is a novel quantitative molecular imaging biomarker that correlates with clinical neurocognitive status and may facilitate more accurate diagnosis, staging, and prognosis of AD. Additional larger scale clinical studies are required to further evaluate the efficacy of this new quantitative index as a diagnostic and prognostic biomarker of AD as well as for the evaluation of safety and efficacy of novel agents undergoing clinical trials for therapy of AD.
      PubDate: 2020-03-09
  • Diagnosis of bladder cancer using 18 F-labeled α
           -methyl-phenylalanine tracers in a mouse model
    • Abstract: Objective Although 2-18F-fluoro-2-deoxy-glucose (18F-FDG) has established roles in the diagnosis of a variety of cancers, it has limited value in the detection of primary/recurrent lesions in the bladder, mainly because of interference by the pooled radioactivity in the urine. Our previous study revealed promising properties of l- and d-2-18F-α-methyl-phenylalanine (2-18F-FAMP) as radiotracers; i.e., their rapid blood clearance and low renal accumulation. In the present study we evaluated the utility of l- and d-2-18F-FAMP for imaging bladder cancer in a mouse model. Methods We used the human bladder cancer cell line HT1376 to prepare a bladder cancer xenograft model in mice bearing both orthotopic and subcutaneous tumors. Biodistribution and PET imaging studies were performed at 1 and 3 h after injection of l-2-18F-FAMP or d-2-18F-FAMP. 18F-FDG was used as a control. Results At 1 h after injection, greater accumulations of both l-2-18F-FAMP and d-2-18F-FAMP were observed in the orthotopic tumors compared to 18F-FDG. The orthotopic tumor-to-muscle ratio of d-2-18F-FAMP was significantly higher than that of 18F-FDG (p < 0.01), because of the rapid blood clearance of d-2-18F-FAMP. l-2-18F-FAMP showed the highest subcutaneous tumor-to-muscle ratio (p < 0.01) due to its high subcutaneous tumor uptake. Compared to l-2-18F-FAMP, d-2-18F-FAMP exhibited faster clearance and lower kidney accumulation. In the PET imaging studies, l- and d-2-18F-FAMP both clearly visualized the orthotopic bladder tumors at 1 h after injection. Conclusion Our study showed that l-2-18F-FAMP and d-2-18F-FAMP have the potential to detect bladder cancer.
      PubDate: 2020-03-06
  • 18 F-FDG maximum standard uptake value predicts PD-L1 expression on tumor
           cells or tumor-infiltrating immune cells in non-small cell lung cancer
    • Abstract: Objectives Programmed cell death-ligand 1 (PD-L1) is expressed on tumor cells (TC) and tumor-infiltrating immune cells (IC). We conducted a retrospective study to investigate the relationship between PD-L1 expression on TC/IC and 18F-FDG uptake in patients with surgically resected non-small cell lung cancer (NSCLC). Methods Total 362 NSCLC patients (297 adenocarcinoma and 65 squamous cell carcinoma) who underwent preoperative 18F-FDG-PET/CT imaging were analyzed retrospectively. Immunohistochemistry analysis was performed for PD-L1 expression on TC and IC in NSCLC specimens with 28–8 antibody. The cut-off value of 5% for defining PD-L1 positivity was determined according to previous trials. The association between PD-L1 expression and clinicopathological variables were analyzed, including age, gender, smoking status, tumor diameter, lymph node metastasis, stage and the maximum standardized uptake value (SUVmax). Results PD-L1 positive expression was 50.8% (184/362) in NSCLC patients. Its positive expression on TC and IC were 24.3% (88/362) and 42.5% (154/362), respectively. SUVmax was significantly higher in patients with PD-L1 positive expression on TC or IC than that with negative. Multivariate analysis demonstrated that PD-L1 expression were correlated with SUVmax. The best cut-off value of SUVmax for PD-L1 expression on TC/IC was 8.5 [area under the curve (AUC) = 0.607, 95% CI 0.549–0.665, P = 0.001, sensitivity 50.5% and specificity 71.4%] determined by ROC curve. Conclusion High SUVmax is linked to PD-L1 expression on TC and IC in our patients with surgically resected non-small cell lung cancer. 18F-FDG-PET/CT imaging may be used to predict the PD-L1 expression on TC and IC in NSCLC patients.
      PubDate: 2020-03-04
  • Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients
           with neuroendocrine tumors who underwent 177 Lu-DOTATOC therapy
    • Abstract: Background Patients with advanced neuroendocrine tumors (NETs) of the midgut are suitable candidates for 177Lu-DOTATOC therapy. Integrated SPECT/CT systems have the potential to help improve the accuracy of patient-specific tumor dosimetry. Dose estimations to target organs are generally performed using the Medical Internal Radiation Dose scheme. We present a novel Monte Carlo-based voxel-wise dosimetry approach to determine organ- and tumor-specific total tumor doses (TTD). Methods A cohort of 14 patients with histologically confirmed metastasized NETs of the midgut (11 men, 3 women, 62.3 ± 11.0 years of age) underwent a total of 39 cycles of 177Lu-DOTATOC therapy (mean 2.8 cycles, SD ± 1 cycle). After the first cycle of therapy, regions of interest were defined manually on the SPECT/CT images for the kidneys, the spleen, and all 198 tracer-positive tumor lesions in the field of view. Four SPECT images, taken at 4 h, 24 h, 48 h and 72 h after injection of the radiopharmaceutical, were used to determine their effective half-lives in the structures of interest. The absorbed doses were calculated by a three-dimensional dosimetry method based on Monte Carlo simulations. TTD was calculated as the sum of all products of single tumor doses with single tumor volumes divided by the sum of all tumor volumes. Results The average dose values per cycle were 3.41 ± 1.28 Gy (1.91–6.22 Gy) for the kidneys, 4.40 ± 2.90 Gy (1.14–11.22 Gy) for the spleen, and 9.70 ± 8.96 Gy (1.47–39.49 Gy) for all 177Lu-DOTATOC-positive tumor lesions. Low- and intermediate-grade tumors (G 1–2) absorbed a higher TTD compared to high-grade tumors (G 3) (signed-rank test, p =  < 0.05). The pre-therapeutic chromogranin A (CgA) value and the TTD correlated significantly (Pearson correlation:  = 0.67, p = 0.01). Higher TTD resulted in a significant decrease of CgA after therapy. Conclusion These results suggest that Monte Carlo-based voxel-wise dosimetry is a very promising tool for predicting the absorbed TTD based on histological and clinical parameters.
      PubDate: 2020-02-29
  • Customized FreeSurfer-based brain atlas for diffeomorphic anatomical
           registration through exponentiated lie algebra tool
    • Abstract: Objective Digital brain template and atlas designed for a specific group provide advantages for the analysis and interpretation of neuroimaging data, but require a significant workload for development. We developed a simple method to create customized brain atlas for diffeomorphic anatomical registration through exponentiated lie algebra (DARTEL) tool using FreeSurfer-generated volume-of-interest (FSVOI) images and validated. Methods 18F-florbetaben positron emission tomography (PET) and magnetic resonance (MR) imaging data were obtained from 248 participants of Alzheimer’s disease spectrum (from cognitively normal to Alzheimer’s disease dementia). To create a customized atlas, MR images of 84 amyloid-negative controls were first processed with FreeSurfer to obtain individual FSVOI and with DARTEL tool to create DARTEL template. Individual FSVOI images were spatially normalized, and each voxel was then labelled with a VOI label with maximum probability. Using these template and atlas, all images were normalized, and the regional standardized uptake value ratios (SUVR) were measured. Results 18F-florbetaben SUVR values measured with customized atlas showed excellent one-to-one correlation with SUVR measured with individual FSVOI in all regions, and thereby showed almost identical between-group comparison results and outperformed the classic methods. Conclusions Customized FreeSurfer-based brain atlas for DARTEL tool is easy to create and useful for the analysis of PET and MR images with high adaptability and reliability for broad research purposes.
      PubDate: 2020-02-22
  • Reply to Zaragori et al.: “Is IDH mutation status associated with 18
           F-FDopa PET uptake”
    • PubDate: 2020-02-04
  • Is IDH mutation status associated with 18 F-FDopa PET uptake'
    • PubDate: 2020-01-30
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762

Your IP address:
Home (Search)
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-